FLNA:NASDAQ
Filana Therapeutics Inc
1,51 $
arrow_upward
+4,14%(+0,060) 1 d.
1,51 $
arrow_downward
-0,02% (-0,00030)bedtimePēctirdzniecības
Slēgts: 1. maijs, 16:00:01 GMT-4 · USD
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: FLNA…
Atvērt
1,44 $
Augsta
1,58 $
Zema
1,44 $
Tirgus kapitalizācija
72,94 milj.
Vid. apjoms
407,12 tūkst.
Apjoms
836,12 tūkst.
Augstākā 52 ned.
2,27 $
Zemākā 52 ned.
1,44 $
Peļņa uz vienu akciju
-1,88 $
Beta
-0,66
Apgrozībā esošās akcijas
48,31 milj.
Darbinieku skaits
19
Ziņas un raksti
No avotiem tīmeklī
Profils
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to company, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason. Wikipedia
Par “Filana Therapeutics Inc”
Ģenerāldirektors-
Darbinieki19
Dibināšanas datums1998
Galvenais birojsOstina, Teksasa, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietne-
MI saturā var būt kļūdas. Uzzināt vairāk